Stryker’s spine business
Stryker (SYK) registered strong growth in recent years. In 1Q17, Stryker reported YoY (year-over-year) growth of ~18.5%. The Neurotechnology & Spine segment contributes the least to Stryker’s revenues out of all the company’s business segments. However, the segment presents immense growth potential for the company. The spine side of the segment has seen a weak performance in recent quarters due to some supply issues in the US.
The company expects strong spine sales in 2Q17 and the rest of the year due to easing supply issues as well as new product launches in its interventional spine and 3D printing and titanium platform. Medtronic (MDT), Nuvasive (NUVA), and Johnson & Johnson (JNJ) are some of the other leading companies in the neurotechnology and spine market. Investors get diversified exposure to Stryker by investing in the Vanguard Total Stock Market ETF (VTI). Stryker accounts for ~0.20% of VTI’s total holdings.
MultiGen 2 radio frequency generator
On July 11, 2017, Stryker announced that it received the FDA 510(k) clearance for its MultiGen 2 RF (radio frequency) generator. The company claims that the next generation of radio-frequency ablation procedure arrived when the device launched. The product is expected to help physicians perform radiofrequency ablation, which is a minimally invasive procedure for facet joint pain, more efficiently with higher reliability and control.
Facet joint pain is the pain at the joint between the two vertebrae in the spine that enables bending and twisting. According to the National Center for Health Statistics, lower back pain impacts around 70 million Americans at any given time.
The MultiGen 2 RF generator provides a customizable procedure platform based on the physician’s preference and patient’s needs. It has flexible stimulation controls. The product is powered with double the industry standard. The target temperature is achieved faster with minimal errors. The product allows physicians to start a procedure by pushing a single button. Physicians can create strip lesions without removing electrodes and simultaneously resolve errors without stopping the procedure. These abilities shorten the time it takes to complete procedures.
Next, we’ll look at the company’s recent product launch in the orthopedics segment.
On July 12, 2017, a US district court judge increased the penalties to be paid by Zimmer Biomet Holdings to Stryker related to its patent infringement case.
Broadcom (AVGO) stock fell ~8.5% after markets closed yesterday following the semiconductor giant's fiscal 2019 second-quarter earnings release. It missed analysts' revenue estimate and cut its fiscal 2019 revenue guidance by $2 billion to $22.5 billion due to sluggishness in its semiconductor solutions business.
The SPDR Gold Shares ETF (GLD), which tracks physical gold prices, has underperformed the broader markets year-to-date, rising just 4.4% compared to the S&P 500’s (SPY) gain of 15.9% as of June 14. The sentiment for gold, however, has been turning around.
Safe havens such as Treasuries and gold were back in favor on June 14 as stocks fell due to rising tensions in the Middle East, concerns over growth, and the looming threat of the US-China trade war. The tech-heavy Nasdaq Composite Index fell 0.67% in the first hour of trading.
Lululemon (LULU) stock rose 2.1% on June 13 in reaction to better-than-expected first-quarter results and an upgraded outlook for fiscal 2019 overall. The company's first-quarter adjusted EPS grew 34.5% to $0.74 on revenue growth of 20.4% to $782.32 million. Analysts had expected EPS of $0.70 and revenue of $755.31 million. Here's why the outlook got an upgrade.
As of 4:40 AM Eastern Time today, US crude oil active futures were at $51.83, ~4% below their closing level in the previous week. If US crude oil prices stay at those levels today, they'll mark their third week of decline in five weeks.
Amazon is discontinuing its Amazon Restaurants service, which has been delivering food for restaurants in parts of the United States. Amazon Restaurants launched in the United States in 2015 and entered the British market the following year. However, it met strong opposition in the British market.